Metabolic health
Blood tests during GLP-1 care: what each result can tell you
Blood tests can help assess diabetes, cardiometabolic risk, and problems arising during treatment. A useful plan asks what decision a test will inform rather than ordering every available marker.
HbA1c and short-term glucose
HbA1c estimates average blood glucose over roughly 3 months, with recent weeks contributing more strongly. NIDDK describes values below 5.7% as the usual normal range, 5.7–6.4% as the prediabetes range, and 6.5% or higher as a diabetes threshold requiring appropriate clinical confirmation.
Anemia, changes in red blood cells, hemoglobin variants, and some other conditions can affect interpretation. A fasting glucose, home glucose reading, and HbA1c measure different things. A clinician should reconcile unexpected differences rather than choosing whichever number looks reassuring.
Sources: NIDDK: the A1C test and diabetes
Kidney measures and hydration
Kidney function can matter because vomiting and diarrhea may cause dehydration and kidney injury. Clinicians may review creatinine, estimated filtration, electrolytes, or other tests when symptoms and medical history justify them.
Ozempic's kidney-risk reduction indication applies to adults with type 2 diabetes and chronic kidney disease. It does not mean that everyone taking any GLP-1 receives the same protection or that dehydration becomes harmless.
Sources: Ozempic prescribing information · Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information
Lipids and other targeted testing
Lipid measures can inform cardiovascular-risk management, while other tests may assess a separate condition or symptom. Changes should be interpreted in the context of diet, weight, other medicines, and existing risk factors rather than attributed automatically to one prescription.
Ask why a test is being ordered, what a concerning result would change, and who reviews it. A thyroid blood test is not a universal clearance test for the MTC/MEN 2 contraindication, and routine tumor-marker screening should not be promised as a proven GLP-1 safety strategy.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information
A useful monitoring conversation
Review baseline diagnoses, diabetes treatment, hypoglycemia risk, pregnancy plans, symptoms, and follow-up access. Ask which blood tests and home measurements are appropriate and when to repeat them. A CGM is a separate decision; it is not required for every weight-management patient.
Keep test results and medicine changes available to the prescriber. Persistent severe symptoms should receive care when they occur rather than wait for a scheduled lab draw.
Sources: NIDDK: the A1C test and diabetes · Wegovy prescribing information, including tablets and Wegovy HD · Mounjaro prescribing information
Ask what decision each test will support
HbA1c can inform diabetes assessment or control, kidney measures may inform a dehydration or chronic-kidney-disease review, and lipids may inform cardiovascular-risk care. Those are different purposes. A broad commercial panel is not inherently more useful than a smaller set chosen for the person's diagnosis and symptoms, and a normal panel cannot exclude every adverse effect.
Before testing, ask what result would change treatment, who interprets it, and when you will receive that interpretation. If a program charges for repeated bundles, request the rationale and whether existing results can be reviewed. A clinician may also need measurements beyond blood tests, such as blood pressure, glucose monitoring when appropriate, symptoms, and physical function. The plan should connect each measure to care rather than collect numbers without a decision pathway.
Sources: NIDDK: the A1C test and diabetes · Ozempic prescribing information · Wegovy prescribing information, including tablets and Wegovy HD · Joint advisory: nutritional priorities to support GLP-1 therapy for obesity
Why HbA1c and a home reading can disagree
HbA1c reflects a longer glucose history, while a home glucose reading concerns a particular moment. Meals, timing, and recent treatment changes can therefore produce different impressions without either measure describing the same question. Conditions affecting red blood cells or hemoglobin can also change HbA1c interpretation. NIDDK recommends appropriate confirmation and evaluation of unexpected results rather than relying on one test alone.
For example, a reassuring morning reading does not establish that glucose has stayed in range throughout the preceding months. Conversely, a longer-term measure may not capture every recent episode of low glucose. Give the clinician the context and other medicines, particularly insulin or sulfonylureas. Do not increase a weight-management dose or discontinue diabetes treatment based only on a result that appears favorable.
Sources: NIDDK: the A1C test and diabetes · Mounjaro prescribing information · Ozempic prescribing information
Symptoms can require care before the next scheduled test
Vomiting and diarrhea can cause dehydration-related kidney injury. A person with persistent symptoms should not wait for the next scheduled creatinine test before contacting the care team. Severe abdominal pain, inability to keep fluids down, fainting, or other significant symptoms require assessment even if baseline results were normal. Laboratory monitoring is one part of care, not a substitute for responding to illness.
Keep the medication list, current dose, symptom dates, and available results together. Ask which changes should be reported and whether a new medicine or diagnosis changes the monitoring plan. Also avoid assuming that a thyroid blood test proves the MTC/MEN 2 contraindication is absent; the label's clinical history questions are separate. A useful follow-up interprets results in context and assigns responsibility for the next action.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information · Ozempic prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.